NIH-funded research R21 grant

Developing imaging agents for detecting alpha-synuclein in Multiple System Atrophy

Official title: Imaging Ligands for Alpha-Synuclein Fibril Accumulation in Multiple System Atrophy

Funded at Washington University · NIH-10581664 · Data updated 2026-11-12

This study is working on a special imaging tool that can help doctors see the buildup of a protein linked to Multiple System Atrophy (MSA) in the brain, which could lead to better diagnosis and understanding of the disease for patients.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionWashington University
NIH-funded
Lab location1 site (Saint Louis, United States)
Project startMarch 1, 2022
Project endFebruary 28, 2026
Funding year2023
Award (this year)$236,250
NIH project number5R21NS123860-02
Project IDNIH-10581664 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with Multiple System Atrophy or those exhibiting symptoms consistent with this condition.

Less likely to help

Patients with other neurodegenerative disorders that do not involve alpha-synuclein accumulation may not benefit from this research.

What this research studies

This research focuses on creating a PET imaging agent that can visualize the accumulation of alpha-synuclein fibrils in patients with Multiple System Atrophy (MSA). By screening various compounds for their ability to bind to these fibrils, the study aims to identify potential leads for a diagnostic tool that can accurately assess disease progression and improve diagnosis. The approach involves both in vitro testing and analysis of postmortem brain tissue to ensure specificity for MSA-related fibrils. If successful, this imaging agent could significantly enhance the understanding and management of MSA.

Why it matters

Potential benefit: If successful, this research could lead to improved diagnostic accuracy and monitoring of disease progression in patients with Multiple System Atrophy.

How similar studies have gone: Previous research has shown promise in developing imaging agents for similar neurodegenerative conditions, indicating potential for success in this novel approach.

Where this research is happening

  • Washington University
    Saint Louis, United States
    Active

Researchers

  • Principal investigator: Kotzbauer, Paul T — Washington University
  • Study coordinator: Kotzbauer, Paul T

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.